Browse the evidence

Gut microbiota composition influences the efficacy of metabolic treatments like bariatric surgery and metformin, and contributes to vagal desensitization in obesity.

If you are on metformin or had bariatric surgery, your gut bacteria matter. A diet that supports a healthy microbiome can enhance the effectiveness of these treatments. Conversely, a poor diet may contribute to 'vagal desensitization,' making weight loss harder.

A higher Oxidative Balance Score (OBS), reflecting a predominance of antioxidant exposures over prooxidants in diet and lifestyle, is positively associated with longer leukocyte telomere length (LTL) in adult females.

For women, maintaining a diet and lifestyle that favors antioxidants over prooxidants is associated with longer telomeres, a marker of cellular aging. This involves consuming foods rich in antioxidants (like fruits, vegetables, whole grains) while minimizing prooxidant stressors like smoking, excessive alcohol, and high processed meat intake. While this study is observational, it suggests that holistic dietary patterns matter more than isolated supplements for preserving cellular longevity.

Aberrant protein posttranslational modifications (PTMs) are central drivers of metabolic diseases including diabetes, obesity, and atherosclerosis, and targeting these modifications offers a viable therapeutic strategy.

Metabolic diseases are driven by complex molecular switches (PTMs) that regulate how your body processes energy. While lifestyle changes are the first line of defense, pharmaceutical interventions targeting these specific molecular pathways (like kinase inhibitors) are increasingly available and effective for managing conditions like diabetes and fatty liver disease when lifestyle changes are insufficient.

Obesity is associated with gut dysbiosis characterized by decreased microbial diversity and an increased Firmicutes/Bacteroidetes ratio, which contributes to obesity through disrupted energy homeostasis, lipid synthesis, and chronic inflammation.

Your gut bacteria play a significant role in how your body handles energy and stores fat. While diet and exercise are crucial, the types of bacteria in your gut can influence your risk of obesity through mechanisms like energy extraction and inflammation. Maintaining gut health through a diverse diet may support metabolic health, but it is not a standalone cure for obesity.

Altered gut microbiota in obesity increases digestible energy uptake from food through enhanced expression of nutrient transporters and fermentation enzymes, leading to increased caloric absorption.

Your gut bacteria can extract more calories from the same amount of food if they are altered. This is one reason why two people might eat the same diet but have different weights. Focusing on gut health through fiber and diverse foods might help optimize energy extraction.

Gut microbiota alterations in obesity contribute to chronic low-grade inflammation through increased lipopolysaccharide (LPS) translocation, which triggers immune responses and insulin resistance.

High levels of bacterial toxins (LPS) can leak into your bloodstream if your gut barrier is compromised, causing inflammation and insulin resistance. A diet rich in fiber and fermented foods may support gut barrier integrity.

Astragaloside IV (AS-IV), a saponin in Astragalus, reduces blood glucose and insulin resistance by modulating intestinal microbiota to increase butyric acid and activating PI3K/AKT and AMPK/SIRT1 signaling pathways.

Astragaloside IV (AS-IV), a key compound in Astragalus, may help lower blood sugar and improve insulin sensitivity. It works by changing gut bacteria to produce more butyric acid and by activating specific cellular pathways that help cells use insulin better. This suggests Astragalus may be beneficial for managing T2DM.

Obesity and metabolic disorders are associated with specific alterations in gut microbiota composition, including enrichment of Proteobacteria and depletion of Faecalibacterium, Akkermansia, and Alistipes, with significant geographic variation in taxa like Prevotella and Ruminococcus.

Focus on dietary patterns that support a diverse microbiome rather than seeking specific 'obesity bacteria' supplements. The link between gut health and obesity is real but complex and varies by geography. Probiotics may have small effects, but they are not a substitute for foundational lifestyle changes.

Elevated levels of pro-inflammatory adipokines (e.g., leptin, resistin, chemerin, FABP4) and reduced levels of anti-inflammatory adipokines (e.g., adiponectin) drive chronic low-grade inflammation in adipose tissue during obesity, contributing to insulin resistance and metabolic disorders.

Obesity involves complex hormonal signaling from fat tissue that promotes inflammation and insulin resistance. While this review focuses on mechanisms rather than direct lifestyle advice, it underscores that metabolic health is influenced by the biochemical environment of fat tissue, not just energy balance. Targeting these inflammatory pathways (e.g., through weight loss or specific medical interventions) may help mitigate metabolic risks.

Leptin acts as a pro-inflammatory cytokine in adipose tissue by promoting macrophage infiltration and activation via JAK/STAT, MAPK, and PI3K pathways, contributing to local inflammation and lipid accumulation.

High levels of leptin in obesity do more than affect hunger; they actively promote inflammation in fat tissue by attracting and activating immune cells (macrophages). This inflammatory state contributes to insulin resistance and other metabolic issues.

Resistin promotes inflammation and insulin resistance by binding to TLR4 and activating NF-kB, JNK, and p38 MAPK pathways in macrophages and hypothalamic cells.

Resistin, a protein elevated in obesity, contributes to inflammation and insulin resistance by activating specific immune pathways (TLR4/NF-kB). This highlights the complex interplay between fat tissue, immune cells, and metabolic health.

Cold exposure activates the beta-3 adrenergic receptor system, leading to UCP1 upregulation and non-shivering thermogenesis, although human response varies significantly compared to rodents.

Cold exposure can activate brown fat via the beta-3 adrenergic system, but human response is highly variable and often weaker than in mice. While you can try cold showers or lower temperatures, do not rely on it as a primary weight loss strategy. Diet and exercise are more reliable and practical methods to increase metabolic rate.

Green extraction technologies (microwave, ultrasound-assisted) are efficient for recovering antioxidants from fruit and vegetable waste streams, offering yields similar to conventional methods with milder operating conditions.

This information is primarily relevant for food scientists and manufacturers. For consumers, it implies that processed foods or supplements derived from 'green extraction' may retain high antioxidant levels, but direct consumption of fresh produce remains the primary source.

Certain pharmaceutical drugs (ACE inhibitors, statins, mTOR inhibitors) and lifestyle interventions (exercise) can increase circulating Klotho levels, potentially offering therapeutic benefits for age-related diseases.

Regular physical activity and adherence to prescribed medications for blood pressure, cholesterol, or metabolic health may naturally support higher Klotho levels. This suggests that standard health maintenance practices contribute to longevity mechanisms.

Calorie restriction (15-30% reduction) inhibits tumor growth and enhances antitumor immunity by reducing IGF-1 signaling, lowering glucose levels, and remodeling the tumor microenvironment to increase CD8+ T cells while decreasing immunosuppressive MDSCs and Tregs.

If you have cancer, discuss with your oncologist whether a supervised calorie restriction of 15-30% might be appropriate as an adjunct to standard therapy. It is not a cure, but it may help improve the effectiveness of your treatment by altering your body's metabolism and immune response.

Ketogenic diets and fasting-mimicking diets may enhance the efficacy of cancer treatments by altering tumor metabolism and immune response, though mechanisms remain largely unexplored.

Ask your oncologist if a ketogenic or fasting-mimicking diet could be a safe adjunct to your cancer treatment. These diets may help your body respond better to therapy, but they are not cures and require careful monitoring.

Insulin resistance is a key feature of PCOS, but routine clinical measurement of insulin resistance is not recommended due to the inaccuracy of currently available measures.

While insulin resistance is common in PCOS, current clinical tests for it are not accurate enough to guide individual treatment decisions. Focus on lifestyle changes (diet, exercise) which improve insulin sensitivity, rather than seeking specific insulin blood tests.

Metformin administration is associated with a reduced incidence of multiple age-related diseases and all-cause mortality in both diabetic and non-diabetic populations.

If you are taking metformin for diabetes, you may already be benefiting from reduced risks of age-related conditions. For non-diabetics considering metformin for longevity, the evidence is promising but not yet definitive (TAME trial pending). Discuss with your doctor, especially regarding kidney function and potential side effects like GI distress, which can often be managed with dosing strategies.

Metformin treatment improves outcomes in osteoarthritis (OA) by reducing inflammation, protecting articular cartilage via the AMPK pathway, and reducing body weight.

For those with osteoarthritis, especially if overweight, metformin (if prescribed for diabetes) may offer additional joint protection and pain relief. This is likely due to its anti-inflammatory properties and weight loss effects. Consult your doctor about whether existing metformin therapy is contributing to joint health.

Metformin use is associated with a reduced risk of various cancers, including breast, colorectal, and pancreatic cancer, though effects on pancreatic cancer prognosis are mixed.

If you have diabetes and take metformin, you may have a lower risk of developing certain cancers like breast and colorectal cancer. However, it is not a cancer treatment itself. Do not stop taking metformin to 'prevent' cancer without consulting your doctor, as the benefits for diabetes management are primary.

Encapsulation techniques (e.g., spray drying, coacervation) protect probiotics from environmental stressors (heat, acid, oxidation) during production, storage, and gastrointestinal transit.

Look for probiotic products that mention 'encapsulation' or 'delayed release.' This technology helps the bacteria survive stomach acid so they can reach your intestines where they are needed.

Advanced stages of MASLD (fibrosis/MASH) causally contribute to heart failure with preserved ejection fraction (HFpEF) through mechanical impediments to hepatic blood flow, reducing right ventricular preload.

If you have advanced liver fibrosis, monitor for signs of heart failure (fatigue, shortness of breath) even if your heart structure looks normal. The stiffness of your liver can mechanically impede blood flow back to the heart, contributing to HFpEF. Managing liver inflammation may help cardiac preload.

In severe diabetes, reduced cardiac lipoprotein lipase (LPL) activity forces cardiomyocytes to rely on non-esterified fatty acids (NEFA) from adipose tissue, causing mitochondrial overload, lipid metabolite accumulation, and cardiac lipotoxicity.

In severe diabetes, the heart's ability to process fat from blood lipids (via LPL) drops. This forces the heart to burn fat directly from the blood (NEFA), which it cannot handle efficiently, leading to damage. Treatments must focus on restoring this specific fat-processing pathway in the heart, not just lowering overall blood fat.

The dual GLP-1/glucagon receptor agonist G49 induces rapid weight loss and metabolic rewiring in diet-induced obese mice by triggering inter-organ crosstalk, specifically white adipose tissue lipolysis, liver ketogenesis/FGF21 release, and subsequent brown adipose tissue activation.

This research suggests that combining GLP-1 and Glucagon receptor activation (like the drug G49) is more effective for weight loss and metabolic health than targeting GLP-1 alone. It works by forcing the body to burn fat (lipolysis) and activate brown fat, mimicking the effects of bariatric surgery. While promising in mice, human clinical data is not yet provided in this paper.